Financier | Commitments |
---|---|
IDA Credit | 20.00 |
P173861
Closed
Nicolas Collin Dit De Montesson , Courtney Ivins
Republic of Honduras
April 9, 2020
(as of board presentation)
April 15, 2020
May 28, 2020
US$ 20.00 million
Ministry of Health (SESAL)
2020
US$ 20.00 million
N/A
Substantial
October 31, 2024
No
BANK APPROVED
April 25, 2024
Financier | Commitments |
---|---|
IDA Credit | 20.00 |
Product Line | IBRD/IDA |
---|---|
IBRD Commitment | N/A |
IDA Commitment | 20.00 |
IBRD + IDA Commitment | 20.00 |
Lending Instrument | |
---|---|
Grant Amount | N/A |
Total Project Cost** | 20.00 |
Period | Financier | Transaction Type | Amount (US$) |
---|---|---|---|
Mar 1, 2023 | IDA-68680 | Loan Disb | 4,000,000.00 |
May 4, 2023 | IDA-66260 | Loan Disb | 176,416.20 |
Apr 15, 2023 | IDA-68680 | Int Charges | 14,102.92 |
Aug 15, 2023 | IDA-66260 | Loan Disb | 600,000.00 |
Sep 13, 2023 | IDA-68680 | Loan Disb | 350,679.06 |
Sep 28, 2023 | IDA-66260 | Loan Disb | 821,545.00 |
Jul 6, 2023 | IDA-68680 | Loan Disb | 1,800,000.00 |
Mar 1, 2024 | IDA-66260 | Loan Disb | -927,797.40 |
Mar 25, 2024 | IDA-66260 | Loan Disb | 417,595.16 |
Mar 25, 2024 | IDA-68680 | Loan Disb | 643,023.50 |
Aug 26, 2024 | IDA-68680 | Loan Disb | 156,293.44 |
May 10, 2024 | IDA-68680 | Loan Disb | 4,287,339.00 |
Jun 27, 2024 | IDA-66260 | Loan Disb | 1,390,512.50 |
Dec 27, 2023 | IDA-68680 | Loan Disb | 191,391.69 |
Apr 15, 2024 | IDA-68680 | Int Charges | 1,287.13 |
Apr 15, 2024 | IDA-68680 | Int Charges | 114,799.35 |
Apr 15, 2024 | IDA-68680 | Int Charges | 114,799.35 |
Apr 15, 2024 | IDA-68680 | Int Charges | 92,761.49 |
Apr 15, 2024 | IDA-66260 | Int Charges | 3,664.19 |
Apr 15, 2024 | IDA-66260 | Int Charges | 120,108.40 |
Apr 15, 2024 | IDA-66260 | Int Charges | 120,108.40 |
Apr 15, 2024 | IDA-66260 | Int Charges | 125,694.83 |
Jun 5, 2023 | IDA-68680 | Loan Disb | 600,784.20 |
Jul 19, 2023 | IDA-68680 | Loan Disb | 40,793.94 |
Oct 15, 2023 | IDA-66260 | Int Charges | 110,841.68 |
Jun 8, 2023 | IDA-66260 | Loan Disb | 536,909.40 |
Dec 26, 2023 | IDA-68680 | Loan Disb | 1,124,385.50 |
Dec 26, 2023 | IDA-66260 | Loan Disb | 417,594.80 |
Oct 15, 2023 | IDA-66260 | Int Charges | 109,416.72 |
Oct 15, 2023 | IDA-66260 | Int Charges | 109,416.72 |
Oct 15, 2023 | IDA-68680 | Int Charges | 77,792.37 |
Oct 15, 2023 | IDA-68680 | Int Charges | 77,792.37 |
Oct 15, 2023 | IDA-68680 | Int Charges | 62,319.57 |
Oct 19, 2023 | IDA-68680 | Loan Disb | 20,441.16 |
Oct 3, 2023 | IDA-68680 | Loan Disb | 314,484.90 |
Oct 15, 2023 | IDA-68680 | Int Charges | 15,106.67 |
Dec 21, 2023 | IDA-66260 | Loan Disb | 417,595.50 |
Dec 21, 2023 | IDA-68680 | Loan Disb | 368,218.56 |
Nov 14, 2023 | IDA-68680 | Loan Disb | 1,960,000.00 |
Apr 15, 2023 | IDA-66260 | Int Charges | 108,159.99 |
Apr 15, 2023 | IDA-68680 | Int Charges | 5,943.95 |
Apr 15, 2023 | IDA-68680 | Int Charges | 5,943.95 |
Apr 15, 2023 | IDA-68680 | Int Charges | 4,860.08 |
Apr 15, 2023 | IDA-68680 | Int Charges | 35,723.95 |
Apr 15, 2023 | IDA-68680 | Int Charges | 35,723.95 |
Apr 15, 2023 | IDA-66260 | Int Charges | 103,352.88 |
Apr 15, 2023 | IDA-66260 | Int Charges | 103,352.88 |
Aug 31, 2022 | IDA-68680 | Loan Disb | 2,780,000.00 |
Oct 15, 2022 | IDA-66260 | Int Charges | 102,128.48 |
Oct 15, 2022 | IDA-66260 | Int Charges | 102,128.48 |
Oct 15, 2022 | IDA-66260 | Int Charges | 106,878.65 |
Sep 26, 2022 | IDA-68680 | Loan Disb | 22,526.10 |
Dec 7, 2022 | IDA-66260 | Loan Disb | 28,651.00 |
Dec 7, 2022 | IDA-66260 | Loan Disb | 118,730.80 |
Oct 13, 2022 | IDA-68680 | Loan Disb | 36,227.55 |
Oct 6, 2022 | IDA-68680 | Loan Disb | 16,535.90 |
Nov 4, 2022 | IDA-66260 | Loan Disb | 78,346.08 |
Apr 25, 2023 | IDA-68680 | Loan Disb | 164,617.00 |
Feb 10, 2023 | IDA-66260 | Loan Disb | 117,519.12 |
Apr 15, 2022 | IDA-66260 | Int Charges | 96,830.54 |
Apr 15, 2022 | IDA-66260 | Int Charges | 96,830.54 |
May 3, 2022 | IDA-66260 | Loan Disb | 800,000.00 |
Aug 30, 2021 | IDA-66260 | Loan Disb | -320.00 |
Apr 15, 2022 | IDA-66260 | Int Charges | 101,335.40 |
Apr 15, 2022 | IDA-66260 | Int Charges | 1.05 |
Apr 15, 2022 | IDA-66260 | Int Charges | 1.05 |
Jul 21, 2022 | IDA-66260 | Loan Disb | -201,548.42 |
Aug 26, 2022 | IDA-68680 | Loan Disb | 2,502.90 |
Dec 27, 2022 | IDA-68680 | Loan Disb | 286,031.50 |
Dec 27, 2022 | IDA-68680 | Loan Disb | 326,047.94 |
Apr 30, 2021 | IDA-66260 | Loan Disb | 88,515.00 |
May 10, 2021 | IDA-66260 | Loan Disb | 49,653.89 |
Oct 15, 2021 | IDA-66260 | Int Charges | 5,600.93 |
Oct 15, 2021 | IDA-66260 | Int Charges | 92,034.38 |
Oct 15, 2021 | IDA-66260 | Int Charges | 92,034.38 |
Oct 15, 2021 | IDA-66260 | Int Charges | 96,315.08 |
Apr 15, 2021 | IDA-66260 | Int Charges | 7,234.94 |
Apr 15, 2021 | IDA-66260 | Int Charges | 7,234.94 |
Apr 15, 2021 | IDA-66260 | Int Charges | 7,571.46 |
Apr 15, 2021 | IDA-66260 | Int Charges | 52,660.22 |
Apr 15, 2021 | IDA-66260 | Int Charges | 52,660.22 |
Apr 15, 2021 | IDA-66260 | Int Charges | 49,508.59 |
Nov 23, 2021 | IDA-66260 | Loan Disb | 925,000.00 |
Aug 31, 2020 | IDA-66260 | Loan Disb | 3,993,010.00 |
Sep 2, 2020 | IDA-66260 | Loan Disb | 61,000.00 |
Dec 21, 2020 | IDA-66260 | Loan Disb | 1,550,137.20 |
Sep 8, 2020 | IDA-66260 | Loan Disb | 529,652.50 |
Dec 21, 2020 | IDA-66260 | Loan Disb | 49,991.34 |
Mar 23, 2021 | IDA-66260 | Loan Disb | 3,432,071.00 |
Dec 29, 2020 | IDA-66260 | Loan Disb | 819,447.90 |
Jan 22, 2021 | IDA-66260 | Loan Disb | 3,600,904.50 |
Apr 7, 2021 | IDA-66260 | Loan Disb | 108,867.00 |
Apr 15, 2020 | IDA-66260 | Loan Commitment | 20,000,000.00 |
Apr 16, 2021 | IDA-68680 | Loan Commitment | 20,000,000.00 |
Name | Review | Date |
---|---|---|
Financial Management | Satisfactory | 2025-01-28 |
Monitoring and Evaluation | Satisfactory | 2025-01-28 |
Overall Implementation Progress (IP) | Satisfactory | 2025-01-28 |
Progress towards achievement of PDO | Highly Satisfactory | 2025-01-28 |
Procurement | Satisfactory | 2025-01-28 |
Project Management | Satisfactory | 2025-01-28 |
INDICATOR | BASELINE | CURRENT | TARGET |
---|
Designated laboratories with COVID-19 diagnostic equipment, test kits, and reagents | Value | 0.00 | 1.00 | 1.00 |
Date | April 1, 2020 | December 8, 2023 | March 31, 2022 | |
Comment |
ICU beds in prioritized ICU units that are fully equipped and operational | Value | 0.00 | 92.00 | 70.00 |
Date | April 1, 2020 | December 8, 2023 | March 31, 2022 | |
Comment |
Percentage of population vaccinated, which is included in the priority population targets, as defined in the National Plan for the Introduction of the Vaccine against COVID-19 | Value | 0.00 | 73.00 | 65.00 |
Date | February 8, 2021 | December 8, 2023 | October 31, 2024 | |
Comment |
Percentage of female population vaccinated, which is included in the priority population targets, as defined in the National Plan for the Introduction of the Vaccine against COVID-19 | Value | 0.00 | 66.00 | 65.00 |
Date | February 8, 2021 | March 3, 2023 | October 31, 2024 | |
Comment |
INDICATOR | BASELINE | CURRENT | TARGET |
---|
Share of prioritized health facilities receiving the volume of PPEs planned under the project | Value | 0.00 | 100.00 | 100.00 |
Date | February 9, 2021 | December 8, 2023 | March 31, 2023 | |
Comment |
Health management and information system to deploy the COVID-19 vaccine is in place, including functionality for identification, registration, and follow-up with COVID-19 vaccine recipients | Value | No | No | Yes |
Date | February 8, 2021 | December 7, 2023 | October 31, 2024 | |
Comment |
Share of vaccination leadership roles created by project financing filled by women | Value | 0.00 | 64.00 | 60.00 |
Date | February 8, 2021 | December 7, 2023 | March 31, 2023 | |
Comment |
Share of regional health authorities reports on corrective measures taken based on feedback from users of health facilities offering COVID-19 vaccination services published on SESAL's website | Value | 0.00 | 100.00 | 100.00 |
Date | February 8, 2021 | December 7, 2023 | March 31, 2023 | |
Comment |